Related Experiment Video
Updated: Mar 28, 2026
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Targeting SDF-1 in multiple myeloma tumor microenvironment
Juliette M C Bouyssou1, Irene M Ghobrial2, Aldo M Roccaro2
1Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, 450 Brookline Avenue, HIM 246, Boston, MA 02215, USA; INSERM UMR 1163, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France.
Multiple myeloma (MM) treatment can be improved by targeting the bone marrow microenvironment. Targeting the SDF-1/CXCR4 axis offers a promising strategy to normalize this supportive environment for better therapeutic outcomes in MM.
Area of Science:
- Oncology
- Hematology
- Cell Biology
Background:
- Multiple myeloma (MM) is an incurable B-cell malignancy.
- The bone marrow (BM) microenvironment significantly influences MM progression.
- The SDF-1/CXCR4 axis plays a key role in MM development within the BM.
Purpose of the Study:
- To review the role of SDF-1 in the MM BM microenvironment.
- To discuss current therapeutic strategies targeting the SDF-1/CXCR4 axis for MM treatment.
Main Methods:
- Literature review of studies on SDF-1, CXCR4, and MM.
- Analysis of the SDF-1/CXCR4 axis in MM pathogenesis and treatment.
Main Results:
- SDF-1 (CXCL12) regulates MM development via its receptor CXCR4.
- Current MM treatments primarily target tumor cells, with limited impact on the BM microenvironment.
- The SDF-1/CXCR4 axis is a viable target for normalizing the MM-supportive BM microenvironment.
Conclusions:
- Targeting the SDF-1/CXCR4 axis presents a promising approach for MM therapy.
- Modulating the BM microenvironment offers a novel strategy to overcome MM treatment limitations.
Related Concept Videos
02:17The Tumor Microenvironment
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...